All posts by bio-anti

New Drug for Episodic Cluster Headache! Lilly Receives FDA Priority Review Designation for A Novel CGRP Antibody Emgality for the Preventive Treatment

Pharmaceutical giant and Company Eli Lilly Recently announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its supplemental Biologics License Application (sBLA) for Emgality (galcanezumab-gnlm) injection forRead More…

New Drugs for Multiple Myeloma! Sanofi CD38 Targeted Antibody Therapy – Isatuximab’s First Phase III Clinical Study was Successful

French pharmaceutical giant Sanofi recently announced that the key phase III clinical study ICARIA-MM to evaluate isatuximab in the treatment of recurrent/refractory multiple myeloma (R/R MM) has reached the main end point. TheRead More…